{"id":"artesunate-amodiaquine-asaq","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL361497","moleculeType":"Small molecule","molecularWeight":"384.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artesunate, a semi-synthetic artemisinin derivative, generates reactive oxygen species that damage parasite proteins and mitochondria. Amodiaquine, a 4-aminoquinoline, accumulates in the parasite's food vacuole and inhibits hemozoin formation, preventing detoxification of heme. The combination provides synergistic activity and helps prevent resistance development.","oneSentence":"Artesunate-amodiaquine is a fixed-dose combination antimalarial that kills malaria parasites through multiple mechanisms: artesunate damages parasite proteins and organelles while amodiaquine interferes with parasite hemoglobin digestion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:33.455Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria (Plasmodium falciparum and other species)"},{"name":"Malaria treatment in children and adults"}]},"trialDetails":[{"nctId":"NCT05951595","phase":"PHASE3","title":"A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-11","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":1680},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":"COVID-19","enrollment":192},{"nctId":"NCT05764746","phase":"PHASE2, PHASE3","title":"Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial","status":"RECRUITING","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2023-05-01","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":384},{"nctId":"NCT03640403","phase":"PHASE3","title":"Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania","status":"COMPLETED","sponsor":"National Institute for Medical Research, Tanzania","startDate":"2019-03-26","conditions":"Malaria,Falciparum, Anemia","enrollment":1555},{"nctId":"NCT06076213","phase":"PHASE4","title":"Test Efficacy Study on the Recommended Antimalarial Drugs in the Democratic Republic of the Congo","status":"COMPLETED","sponsor":"Ministry of Public Health, Democratic Republic of the Congo","startDate":"2023-05-01","conditions":"Uncomplicated Plasmodium Falciparum Malaria","enrollment":1260},{"nctId":"NCT05550909","phase":"PHASE2","title":"Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-10-17","conditions":"Malaria,Falciparum","enrollment":100},{"nctId":"NCT06300970","phase":"PHASE4","title":"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-08-09","conditions":"Plasmodium Falciparum, Malaria, Uncomplicated Malaria","enrollment":352},{"nctId":"NCT04618523","phase":"PHASE4","title":"Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo","status":"COMPLETED","sponsor":"Ministry of Public Health, Democratic Republic of the Congo","startDate":"2020-10-26","conditions":"Malaria","enrollment":1117},{"nctId":"NCT02627456","phase":"PHASE1","title":"Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-09","conditions":"Malaria","enrollment":409},{"nctId":"NCT04829695","phase":"PHASE4","title":"Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Malaria in Cameroon","status":"UNKNOWN","sponsor":"University of Yaounde 1","startDate":"2021-04-05","conditions":"Falciparum Malaria","enrollment":184},{"nctId":"NCT03773536","phase":"PHASE4","title":"Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar","status":"COMPLETED","sponsor":"Professor Anders Björkman","startDate":"2017-05-09","conditions":"Plasmodium Falciparum Malaria","enrollment":146},{"nctId":"NCT03768908","phase":"PHASE4","title":"Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005","status":"COMPLETED","sponsor":"Professor Anders Björkman","startDate":"2005-01-05","conditions":"Plasmodium Falciparum Malaria","enrollment":359},{"nctId":"NCT03764527","phase":"PHASE4","title":"Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar","status":"COMPLETED","sponsor":"Professor Anders Björkman","startDate":"2002-11-01","conditions":"Plasmodium Falciparum Malaria","enrollment":408},{"nctId":"NCT03431714","phase":"PHASE4","title":"Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania","status":"COMPLETED","sponsor":"National Institute for Medical Research, Tanzania","startDate":"2017-07-14","conditions":"Uncomplicated Falciparum Malaria","enrollment":333},{"nctId":"NCT02741024","phase":"PHASE4","title":"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2013-10","conditions":"Malaria","enrollment":288},{"nctId":"NCT02637128","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-03","conditions":"MALARIA, FALCIPARUM","enrollment":452},{"nctId":"NCT00808951","phase":"PHASE4","title":"In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso","status":"COMPLETED","sponsor":"Centre Muraz","startDate":"2008-12","conditions":"Malaria","enrollment":440},{"nctId":"NCT01697787","phase":"PHASE4","title":"Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso","status":"COMPLETED","sponsor":"Centre Muraz","startDate":"2012-10","conditions":"Malaria","enrollment":150},{"nctId":"NCT01017770","phase":"PHASE4","title":"Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso","status":"COMPLETED","sponsor":"Centre Muraz","startDate":"2008-09","conditions":"Uncomplicated P. Falciparum Malaria in Children","enrollment":340},{"nctId":"NCT01023399","phase":"PHASE4","title":"Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-11","conditions":"Malaria","enrollment":580},{"nctId":"NCT00393679","phase":"PHASE3","title":"Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2007-07","conditions":"Fever, Malaria","enrollment":4112},{"nctId":"NCT01378286","phase":"PHASE3","title":"Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-01","conditions":"Malaria","enrollment":380},{"nctId":"NCT01567423","phase":"NA","title":"Efficacy Study of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria","status":"COMPLETED","sponsor":"Epicentre","startDate":"2008-04","conditions":"Malaria, Falciparum","enrollment":301},{"nctId":"NCT00374205","phase":"PHASE4","title":"Randomized Trial on Effectiveness of ACTs in Ghana","status":"TERMINATED","sponsor":"Bernhard Nocht Institute for Tropical Medicine","startDate":"2006-09","conditions":"Malaria, Falciparum","enrollment":245}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Coarsucam"],"phase":"marketed","status":"active","brandName":"Artesunate-Amodiaquine (ASAQ)","genericName":"Artesunate-Amodiaquine (ASAQ)","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artesunate-amodiaquine is a fixed-dose combination antimalarial that kills malaria parasites through multiple mechanisms: artesunate damages parasite proteins and organelles while amodiaquine interferes with parasite hemoglobin digestion. Used for Uncomplicated malaria (Plasmodium falciparum and other species), Malaria treatment in children and adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}